Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stock Watch: The Two Sides Of A Complete Response Letter

Acadia Comes Out Guns Blazing While The FDA’s Hands Are Tied

Executive Summary

The FDA’s rejection of Acadia’s label expansion into a broader patient population for its only approved drug resulted in an aggrieved reaction. Better disclosure from both sides would have helped.

You may also be interested in...



Stock Watch: The Rise Of Vaccine Cannibalism

Influenza and pneumococcal vaccine sales were initially strong at the start of the pandemic. Recent weak revenues for travel, childhood and premium vaccines could raise population immunity concerns, however.

Stock Watch: Rollercoaster For Pfizer; Doldrums For Esperion

An early high for Pfizer with its strong first-quarter results was followed by patent waiver worries. At the other end of the spectrum, Esperion reminded us of the challenges in making a commercial success as a small biopharma firm in the pandemic.

Stock Watch: Novartis And Lilly Pour Cold Water On Q1 Earnings

Novartis’s comparatively anemic revenue growth and Lilly’s sales shortfall suggest that hopes for an immediate sector recovery from the pandemic are premature.

Topics

Related Companies

UsernamePublicRestriction

Register

SC144147

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel